Loading
A phase 2 trial of Palbociclib, Temozolomide, FOLFIRI in ewing sarcoma and rhabdomyosarcoma, run by Pfizer, active and no longer recruiting.
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors is a phase 2 interventional study registered as NCT03709680 by Pfizer, with 128 participants enrolled, started 2019-05-24 and due to reach its primary completion in 2024-08-26. Interventions recorded: Palbociclib, Temozolomide, Irinotecan, Topotecan, Cyclophosphamide. Conditions listed: Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma. No results are recorded here; the registry entry is the source.
Shares Ewing sarcoma, CDK4/6 inhibitors, Temozolomide, Cytotoxic chemotherapy.
Shares Topotecan, FOLFIRI (5-FU, leucovorin, irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Temozolomide, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.
Shares Palbociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen).
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.
Shares Topotecan, Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy.